Effecting New Antibiotics, Part II: Microbial Genomics
This article was originally published in Start Up
Executive SummaryThe emerging science of microbial genomics is propelling an array of corporate efforts to develop novel antibiotics effective against drug-resistant organisms. Firms compiling genomic databases have been the first to profit, but competition is dropping the price of access.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.